ScandiDos has completed a directed share issue of 4,150,000 shares at a subscription price of SEK 3 per share

The Board of Directors of ScandiDos has, with the support of the issue authorization from the Annual General Meeting on October 20, 2021, resolved on the Directed Issue. The subscription price per share corresponds to a premium of approximately 8 percent compared to the average price during the last 12 months.

The strategic alliance that is being created between ScandiDos and IBA in quality assurance for radiation therapy enables a collaboration between the parties in product development, marketing, and distribution in selected markets. Details of the cooperation will be developed jointly by the parties in the coming months.

"IBA and ScandiDos have a common understanding of the value of a complete package of solutions for quality assurance of radiation therapy and this has been fundamental in the creation of this alliance between the companies. By partnering with IBA, a leading industry player, ScandiDos will be able to reach more customers globally and help make radiation treatments even safer than they are today. This strategic collaboration will allow us to maintain our independence to continue to develop our business while benefiting from IBA's strong operational capabilities", says Gustaf Piehl, CEO ScandiDos.

"This is an important milestone in our ongoing strategy around industry consolidation. We are proud that ScandiDos has chosen us as their partner for their expansion. For many years, we have been impressed with the quality of ScandiDos’ product portfolio in patient quality assurance and believe that it complements our rapidly growing hardware and software offering well. The combination of the companies' product offerings will provide a unique level of quality, simplicity and versatility to the medical physicists, allowing them to deliver radiation treatments to their full potential, with increased safety to cancer patients everywhere," says Jean-Marc Bothy, President IBA Dosimetry.

ScandiDos intends to use the proceeds from the issue to finance the continued implementation of the company's strategic and operational plans.

The reasons for the deviation from the shareholders' preferential rights are to strengthen the Company's both financial and operational position through an investment from a strategic player that can offer ScandiDos good cooperation opportunities. Through the Directed Issue, the Company receives financing in a fast and efficient manner, not least as the costs are significantly lower than in the case of a customary capital raising through a preferential rights issue. The Board's overall assessment is that the reasons for carrying out a directed issue outweigh the reasons that speak in favor of carrying out a preferential rights issue, i.e. an issue with preferential rights for the shareholders. The Board's assessment is that the time- and cost-effective financing is in the interest of all shareholders, not least in light of the fact that no discount was provided in the issue, which was instead carried out with a certain premium / surcharge in relation to the market price.

Subscription of the new shares shall take place no later than 1 September 2022. However, IBA has already undertaken to subscribe and pay for the new shares under a separate subscription commitment.

The Directed Issue entails a dilution of approximately 9% percent of the number of shares and votes in the Company (calculated as the number of newly issued shares divided by the total number of shares in the Company after the Directed Issue). Through the Directed Issue, the number of shares and votes in the Company increases by 4,150,000 from 41,458,870 to 45,608,870. The share capital increases by SEK 207,500, from SEK 2,072,944 to SEK 2,280,444.

Counsellor
Lindahl Law firm has acted as the Company's legal advisor in connection with the Directed Issue.

About ScandiDos
ScandiDos is an innovative and forward-thinking company with groundbreaking software and hardware solutions for patient quality assurance in modern radiation therapy. The Delta4 product family delivers a complete quality assurance solution that makes the treatment process safe and efficient. We strengthen the trust of the staff of radiation therapy clinics by providing them with an independent receipt that the advanced and complicated treatment can be delivered and has been delivered as prescribed.

The head office is located in Uppsala Science Park where product development is conducted. Sales are made through sales offices in the USA, Malaysia and France, directly in the Nordic countries and through distributors in over 50 countries.

ScandiDos is listed on NASDAQ First North Stockholm with the ticker code SDOS. Certified advisor is Erik Penser Bank (08-463 83 00, certifiedadviser@penser.se). Additional investor information can be found on www.scandidos.com . Product information can be found on www.Delta4family.com

About IBA
IBA Group (Ion Beam Applications S.A) is the world's leading supplier of particle accelerator technology. The company is a leading provider of equipment and services in the proton therapy field, considered the most advanced form of radiation therapy available today. IBA is also a leading supplier in the areas of industrial sterilization, radiopharmaceuticals and dosimetry. The company, which is based in Louvain-la-Neuve, Belgium, has approximately 1600 employees globally. IBA is a certified B Corp company that meets the highest standards of social and environmental sustainability.

IBA is listed on the pan-European exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB:BB. For more information, see: www.iba-worldwide.com